MaxCyte, Inc. (MXCT) Dividend History

Company News

• Global Transfection Technologies Market Predicted to Surpass USD 2.33 billion, at a CAGR of 9.0% by 2032 - Report ... - GlobeNewswire

  The global transfection technologies market is expected to grow at a CAGR of 9.0% from 2024 to 2032, driven by the rising demand for protein production and advancements in biotechnology.

  GlobeNewswire Inc.

  Featured Companies: BIO BIO.B
• Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?

  The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  Zacks Investment Research
• Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why

  MaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

  Zacks Investment Research
• MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

  ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th at 2:40 pm CT.

  GlobeNewswire Inc.
• MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

  Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells. Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells.

  GlobeNewswire Inc.